Last updated: November 2, 2026
Orexo prevailed against Actavis in Hatch-Waxman litigation involving Zubsolv, its buprenorphine/naloxone sublingual tablet for opioid-use-disorder treatment. The dispute centered on U.S. Patent No. 8,940,330, which covers aspects of Orexo’s rapidly disintegrating sublingual formulation. The District of Delaware found the asserted claims valid and infringed, and the Federal Circuit affirmed in 2018. The decision materially delayed Actavis’ generic launch until expiration of the asserted patent, subject to any later agreement or regulatory developments. (Orexo AB v. Actavis Elizabeth LLC, 2018)
What was Orexo AB v. Actavis Elizabeth LLC about?
The case was a Hatch-Waxman patent action filed after Actavis submitted an Abbreviated New Drug Application for a generic version of Zubsolv.
| Item |
Detail |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:17-cv-00205 |
| Plaintiff |
Orexo AB |
| Defendant |
Actavis Elizabeth LLC |
| Reference product |
Zubsolv, buprenorphine and naloxone sublingual tablets |
| NDA holder |
Orexo US, Inc. and Orexo AB-related entities |
| Asserted patent |
U.S. Patent No. 8,940,330 |
| Patent title |
Pharmaceutical composition |
| Federal Circuit citation |
903 F.3d 1265 |
| Filing basis |
Actavis ANDA submission and Paragraph IV certification |
| Outcome |
Orexo prevailed; asserted claims upheld and infringement judgment affirmed |
Orexo alleged that Actavis’ proposed generic product would infringe claims covering the composition and performance characteristics of the Zubsolv tablet. Actavis challenged the patent on invalidity grounds, principally obviousness.
What patent protected Zubsolv in the Actavis litigation?
The central patent was U.S. Patent No. 8,940,330, commonly referred to as the ’330 patent. The patent claimed a pharmaceutical composition containing buprenorphine and naloxone in a sublingual tablet designed to disintegrate rapidly in the mouth.
The claimed technology addressed several formulation objectives:
- Delivery of buprenorphine and naloxone through the sublingual mucosa.
- Rapid tablet disintegration.
- Adequate drug release and absorption.
- A relatively small dosage form compared with earlier buprenorphine/naloxone products.
- Commercially acceptable taste and administration characteristics.
The asserted claims covered composition and formulation limitations rather than the active ingredients alone. The case therefore turned on the technical combination of ingredients, tablet structure and performance, not on ownership of buprenorphine or naloxone as active pharmaceutical ingredients.
What were the key patent claims?
The litigation focused on claims that required a sublingual pharmaceutical composition containing buprenorphine and naloxone, together with formulation characteristics that distinguished the Zubsolv product from prior buprenorphine/naloxone dosage forms.
The precise claim construction and infringement analysis examined whether the Actavis formulation met the limitations of the asserted claims. The District Court concluded that the proposed Actavis product fell within the relevant claim scope. The Federal Circuit affirmed that determination.
The ’330 patent was important because it protected the dosage-form technology that differentiated Zubsolv from Suboxone tablets and films. It was not a broad patent on treatment of opioid dependence or on buprenorphine/naloxone therapy generally.
When was the Orexo v. Actavis lawsuit filed?
Orexo filed the case in 2017 after Actavis notified Orexo of its Paragraph IV certification. The case number is 1:17-cv-00205. The litigation arose from Actavis’ ANDA seeking approval to market a generic buprenorphine/naloxone sublingual tablet before expiration of the ’330 patent.
Under the Hatch-Waxman framework, the Paragraph IV notice created a patent dispute and triggered the statutory 30-month stay on FDA approval of the ANDA, unless the litigation ended earlier or the stay was otherwise terminated.
The case was part of a broader effort by generic manufacturers to enter the buprenorphine/naloxone market. Generic competition posed a direct risk to Zubsolv because the product competed in a treatment category with substantial prescription volume and reimbursement sensitivity.
What did the District of Delaware decide?
The District Court determined that the asserted claims of the ’330 patent were not invalid and that Actavis’ proposed product infringed the patent.
Actavis’ principal invalidity theory was obviousness under 35 U.S.C. § 103. The defense relied on prior-art references relating to buprenorphine/naloxone products, sublingual delivery and rapidly disintegrating tablets.
The Court rejected the obviousness challenge. Its analysis credited the differences between the claimed formulation and the prior art, as well as evidence that the claimed composition achieved relevant performance and commercial results. The judgment prevented FDA approval of Actavis’ ANDA before patent expiration.
The District Court’s decision also reflected the structure of Hatch-Waxman litigation. The question was not whether Actavis had commercial capacity to manufacture a generic tablet. The question was whether the proposed ANDA product could be approved before the expiration of a patent that covered the formulation.
How did the Federal Circuit rule in Orexo v. Actavis?
The Federal Circuit affirmed the District Court in Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).
The appellate court upheld the conclusion that the asserted claims were nonobvious. The court considered the prior art, the differences between the prior-art formulations and the claimed composition, and objective evidence supporting patentability.
The Federal Circuit’s decision was commercially important for two reasons:
- It preserved the enforceability of the ’330 patent against Actavis’ proposed generic product.
- It confirmed that formulation patents can block ANDA approval when the claimed combination produces a distinct dosage-form profile, even where the active ingredients and general therapeutic use are already known.
The decision did not create a broad monopoly over all buprenorphine/naloxone products. Its effect was limited to the patent claims and the proposed Actavis product at issue.
What was the Paragraph IV challenge?
Actavis’ Paragraph IV certification asserted that the relevant Zubsolv patent was invalid, unenforceable or not infringed. Paragraph IV certifications are used when an ANDA applicant seeks FDA approval before expiration of an Orange Book-listed patent.
The certification allowed Actavis to challenge the patent without waiting for expiration. It also exposed Actavis to infringement litigation under 35 U.S.C. § 271(e)(2), which treats the ANDA filing itself as an artificial act of infringement for purposes of resolving the patent dispute.
The litigation did not establish that every generic buprenorphine/naloxone tablet would infringe the ’330 patent. It established that Actavis’ particular proposed product was within the asserted claims and that the claims survived the invalidity challenge.
What was the patent expiration date for the ’330 patent?
U.S. Patent No. 8,940,330 has a listed expiration date in February 2027, subject to any applicable patent-term adjustment, extension or correction reflected in the official patent and Orange Book records. The key commercial protection at issue in the Actavis case therefore extended into 2027.
| Protection |
Approximate endpoint |
| U.S. Patent No. 8,940,330 |
February 2027 |
| Hatch-Waxman 30-month stay |
Dependent on notice and case timing |
| Federal Circuit affirmance |
2018 |
| Earliest ordinary generic approval under the litigated patent |
After patent protection, unless authorized earlier |
Patent expiration does not by itself guarantee immediate generic market entry. FDA approval, manufacturing readiness, other listed patents, regulatory exclusivity and any settlement terms can affect launch timing.
What was the Orange Book status of Zubsolv?
Zubsolv is an FDA-approved product containing buprenorphine and naloxone for maintenance treatment of opioid dependence, now generally described within the FDA’s opioid-use-disorder treatment framework.
The Orange Book lists patents associated with approved Zubsolv presentations. The ’330 patent was the central patent asserted against Actavis in this litigation. Orange Book listings are product-specific and should be distinguished from the entire Orexo patent estate, which may include formulation, manufacturing and other intellectual-property rights not all asserted in this action. (FDA, Approved Drug Products with Therapeutic Equivalence Evaluations)
The regulatory effect of an Orange Book listing is significant. An ANDA applicant must address listed patents through certifications, and a Paragraph IV certification can trigger patent litigation and the 30-month approval stay.
Did Orexo and Actavis settle the case?
The reported appellate decision reflects a merits victory for Orexo, not a settlement-based disposition. The Federal Circuit affirmed the judgment after reviewing the District Court’s validity and infringement conclusions.
No settlement term should be inferred from the appellate judgment. A later commercial agreement, authorized generic arrangement or license would require separate evidence and should not be treated as part of the reported holding in 903 F.3d 1265.
For commercial diligence, the relevant distinction is:
- The reported case ended with judicial findings favorable to Orexo.
- The decision did not disclose an authorized generic launch right for Actavis.
- The opinion did not establish a royalty-bearing license or agreed early-entry date.
- Any later agreement would need to be evaluated separately from the reported litigation outcome.
What litigation risk did Actavis face?
Actavis faced the risk that FDA approval of its ANDA would be delayed until expiration of the ’330 patent. Once the District Court found infringement and upheld validity, the economic value of an early launch declined sharply.
The principal risks were:
- Loss of the first generic launch opportunity.
- Delay in obtaining FDA approval.
- Development and manufacturing costs incurred without immediate commercialization.
- Potential damages exposure if the product were launched before a final enforceability or infringement resolution.
- Reduced ability to compete on price against Zubsolv and other buprenorphine/naloxone products.
The Federal Circuit affirmance removed the main appellate path for Actavis to obtain early entry based on the invalidity arguments presented in that case.
How strong was Orexo’s patent position?
The ’330 patent had meaningful litigation strength against the accused Actavis product because it survived both trial-level and appellate review. Its strength rested on four factors:
- The claims were directed to a specific formulation rather than a broad therapeutic concept.
- The District Court found infringement by the proposed generic product.
- The Federal Circuit affirmed the nonobviousness determination.
- The patent reached beyond the active ingredients to dosage-form characteristics relevant to product performance.
The patent’s strength was narrower than a platform patent covering all sublingual buprenorphine/naloxone products. A different generic formulation could present a different infringement and invalidity analysis.
How did the case affect generic launch scenarios?
The decision supported three principal launch scenarios.
Launch after patent expiration
This was the lowest-risk path for Actavis. FDA approval could proceed after the relevant patent barrier ended, assuming the ANDA satisfied regulatory requirements and no other patent or exclusivity barrier remained.
Launch under a later license or settlement
Orexo could have authorized earlier entry through a license or settlement. The reported appellate decision does not establish that such an arrangement existed.
At-risk launch
Actavis could have launched before the patent expired, accepting potential infringement liability. The adverse District Court judgment and Federal Circuit affirmance made this option materially riskier.
How does Orexo’s Zubsolv patent estate compare with Suboxone protection?
Zubsolv and Suboxone both use buprenorphine and naloxone, but their commercial differentiation includes formulation, dosage form, taste, disintegration and administration characteristics.
| Issue |
Zubsolv |
Suboxone |
| Active ingredients |
Buprenorphine/naloxone |
Buprenorphine/naloxone |
| Main product forms |
Sublingual tablet and other approved presentations |
Sublingual film and tablets |
| Patent strategy |
Formulation and product-specific protection |
Film, formulation and product-specific protection |
| Actavis case |
’330 patent |
Not the patent at issue |
| Generic risk |
Dependent on formulation claims and Orange Book listings |
Dependent on separate patents, certifications and litigation |
The Orexo decision illustrates why an active-ingredient comparison is insufficient. Competing products may share the same molecules while relying on different patent claims covering delivery systems and product architecture.
What is the current litigation status?
The reported litigation is concluded at the appellate level. The Federal Circuit’s 2018 decision affirmed Orexo’s favorable judgment against Actavis. The case is therefore not an open trial-stage dispute based on the reported record.
The continuing business question is whether other generic applicants challenged separate Zubsolv patents or developed non-infringing formulations. Those issues are distinct from the final judgment in 1:17-cv-00205.
Key Takeaways
- Orexo sued Actavis over an ANDA for generic Zubsolv.
- The central patent was U.S. Patent No. 8,940,330.
- The District Court found the asserted claims valid and infringed.
- The Federal Circuit affirmed in 2018 in 903 F.3d 1265.
- The case delayed Actavis’ proposed generic entry until the relevant patent barrier ended, absent a later license or settlement.
- The decision strengthened Orexo’s formulation-patent position but did not create a monopoly over all buprenorphine/naloxone products.
- The principal commercial protection associated with the case extended into February 2027.
- Generic entry required analysis of the ’330 patent, other Orange Book listings, FDA approval status and any later commercial agreements.
FAQs
What drug was at issue in Orexo v. Actavis?
The case involved Zubsolv, a buprenorphine/naloxone sublingual tablet used for opioid-use-disorder treatment.
Which patent did Orexo assert against Actavis?
Orexo principally asserted U.S. Patent No. 8,940,330, covering a pharmaceutical composition used in the Zubsolv sublingual formulation.
Did Actavis win its obviousness challenge?
No. The District Court rejected the obviousness challenge, and the Federal Circuit affirmed the judgment.
Did the Federal Circuit invalidate the Zubsolv patent?
No. The Federal Circuit upheld the relevant patentability and infringement conclusions in favor of Orexo.
Could another generic manufacturer avoid the Orexo patent?
Potentially. The judgment concerned Actavis’ proposed product. A different formulation would require a separate claim-construction, infringement and validity analysis.
References
- Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).
- U.S. Patent No. 8,940,330. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- 21 U.S.C. § 355(j).
- 35 U.S.C. § 271(e)(2).
